Wall Street Zen Downgrades Dyne Therapeutics (NASDAQ:DYN) to Strong Sell

Key Points

• Wall Street Zen downgraded Dyne Therapeutics (NASDAQ:DYN) from a "sell" to a "strong sell" in a research note issued Saturday.
• Despite that downgrade, analysts hold a consensus rating of "Moderate Buy" with a $35.14 price target; DYN trades around $17.39 (1‑year range $8.06–$25.00) and recently reported an EPS of ($0.76) versus ($0.74) expected.
• Insiders have been net sellers recently—1,446,188 shares (~$27.8M) sold over the last 90 days—though one director bought 3,000 shares; insiders own about 14.14% of the company.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued to investors on Saturday.

DYN has been the subject of a number of other research reports. Jefferies Financial Group restated a "buy" rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. HC Wainwright dropped their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, March 3rd. JPMorgan Chase & Co. reduced their target price on shares of Dyne Therapeutics from $17.00 to $16.00 and set a "neutral" rating for the company in a research report on Tuesday, January 20th. Morgan Stanley decreased their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an "overweight" rating for the company in a research note on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.14.

Dyne Therapeutics Price Performance

DYN opened at $17.39 on Friday. Dyne Therapeutics has a 1 year low of $8.06 and a 1 year high of $25.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -4.91 and a beta of 1.08. The firm's fifty day moving average price is $17.89 and its two-hundred day moving average price is $18.50.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.02). As a group, analysts anticipate that Dyne Therapeutics will post -2.94 earnings per share for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, Director Brian S. Posner bought 3,000 shares of Dyne Therapeutics stock in a transaction dated Friday, March 6th. The stock was purchased at an average price of $15.06 per share, for a total transaction of $45,180.00. Following the completion of the purchase, the director directly owned 11,500 shares of the company's stock, valued at approximately $173,190. This trade represents a 35.29% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jason P. Rhodes sold 227,337 shares of the company's stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $18.38, for a total transaction of $4,178,454.06. Following the sale, the director owned 8,511 shares in the company, valued at $156,432.18. The trade was a 96.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,446,188 shares of company stock worth $27,758,128 over the last 90 days. 14.14% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds have recently made changes to their positions in the stock. Hilton Head Capital Partners LLC purchased a new stake in Dyne Therapeutics during the 1st quarter worth about $26,000. Chung Wu Investment Group LLC purchased a new stake in shares of Dyne Therapeutics in the third quarter worth about $30,000. Strs Ohio purchased a new position in Dyne Therapeutics during the fourth quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Dyne Therapeutics by 25.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company's stock worth $70,000 after acquiring an additional 1,109 shares during the period. Finally, Aster Capital Management DIFC Ltd purchased a new stake in Dyne Therapeutics in the 4th quarter worth approximately $84,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.